| Assay ID | Title | Year | Journal | Article |
|---|
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347412 | qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1911536 | Antiproliferative activity against mouse BaF3 cells expressing TEL-FGFR4 assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay | 2022 | Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
| Discovery of 1,6-Naphthyridin-2(1 |
| AID1911529 | Antiproliferative activity against human Hep3B cells expressing FGF19/FGFR4 assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay | 2022 | Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
| Discovery of 1,6-Naphthyridin-2(1 |
| AID1911526 | Antiproliferative activity against human RT-112 cells expressing FGFR3 assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay | 2022 | Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
| Discovery of 1,6-Naphthyridin-2(1 |
| AID1717908 | Hepatic extraction ratio in rat liver microsomes preincubated for 3 mins followed by NADPH addition and measured after 60 mins | 2020 | Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
| Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4. |
| AID1778527 | Inhibition of FGFR4 (unknown origin) | 2021 | European journal of medicinal chemistry, Aug-05, Volume: 220 | Design, synthesis and biological evaluations of a series of Pyrido[1,2-a]pyrimidinone derivatives as novel selective FGFR inhibitors. |
| AID1601508 | Inhibition of FGFR1 (unknown origin) using poly[Glu:Tyr] (4:1) substrate and ATP and [gamma33P]-ATP incubated for 30 mins | 2019 | Journal of medicinal chemistry, 03-28, Volume: 62, Issue:6
| Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects. |
| AID1911598 | Inhibition of FGFR3 (unknown origin) incubated for 30 mins by trilux reader method | 2022 | Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
| Discovery of 1,6-Naphthyridin-2(1 |
| AID1904739 | Inhibition of FGFR2 (unknown orgin) using Tyr 04 peptide as substrate incubated for 1 hr in presence of 5 uM ATP by FRET based Z'-LYTE assay | | | |
| AID1717930 | Inhibition of recombinant non-phosphorylated FGFR4 kinase domain (442 to 753) (unknown origin) expressed in Sf9 insect cells using 5-Fluo-Ahx-KKKKEEIYFFFG-NH2 peptide as substrate in presence of ATP measured after 60 mins by caliper microfluidic mobility | 2020 | Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
| Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4. |
| AID1601512 | Selectivity index, ratio of IC50 for VEGFR2 (unknown origin) to IC50 for FGFR1 (unknown origin) | 2019 | Journal of medicinal chemistry, 03-28, Volume: 62, Issue:6
| Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects. |
| AID1904743 | Antiproliferative activity against human Hep3B cells assessed as inhibition of cell growth incubated for 5 days by SRB assay | | | |
| AID1911596 | Inhibition of FGFR1 (unknown origin) incubated for 30 mins by trilux reader method | 2022 | Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
| Discovery of 1,6-Naphthyridin-2(1 |
| AID1601515 | Selectivity index, ratio of IC50 for VEGFR2 (unknown origin) to IC50 for FGFR4 (unknown origin) | 2019 | Journal of medicinal chemistry, 03-28, Volume: 62, Issue:6
| Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects. |
| AID1904741 | Antiproliferative activity against mouse BAF3 cells expressing wild-type FGFR4 assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay | | | |
| AID1904742 | Antiproliferative activity against human MDA-MB-453 cells assessed as inhibition of cell growth incubated for 5 days by SRB assay | | | |
| AID1778524 | Inhibition of FGFR1 (unknown origin) | 2021 | European journal of medicinal chemistry, Aug-05, Volume: 220 | Design, synthesis and biological evaluations of a series of Pyrido[1,2-a]pyrimidinone derivatives as novel selective FGFR inhibitors. |
| AID1778526 | Inhibition of FGFR3 (unknown origin) | 2021 | European journal of medicinal chemistry, Aug-05, Volume: 220 | Design, synthesis and biological evaluations of a series of Pyrido[1,2-a]pyrimidinone derivatives as novel selective FGFR inhibitors. |
| AID1904737 | Inhibition of N-terminal 6His-tagged FGFR4 (unknown orgin) (445 to 753 residues) expressed in Rosetta (NEB) cells using Tyr 04 peptide as substrate incubated for 1 hr in presence of 150 uM ATP by FRET based Z'-LYTE assay | | | |
| AID1601513 | Selectivity index, ratio of IC50 for VEGFR2 (unknown origin) to IC50 for FGFR2 (unknown origin) | 2019 | Journal of medicinal chemistry, 03-28, Volume: 62, Issue:6
| Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects. |
| AID1911599 | Inhibition of FGFR4 (unknown origin) incubated for 30 mins by trilux reader method | 2022 | Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
| Discovery of 1,6-Naphthyridin-2(1 |
| AID1313609 | Selectivity ratio of IC50 for recombinant human VEGFR2 to IC50 for recombinant human FGFR1 | 2016 | Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
| Discovery of 3-(5'-Substituted)-Benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis, and Biological Evaluation. |
| AID1904740 | Inhibition of FGFR3 (unknown orgin) using Tyr 04 peptide as substrate incubated for 1 hr in presence of 75 uM ATP by FRET based Z'-LYTE assay | | | |
| AID1911535 | Antiproliferative activity against human NCI-H1581 cells expressing FGFR1 assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay | 2022 | Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
| Discovery of 1,6-Naphthyridin-2(1 |
| AID1904738 | Inhibition of FGFR1 (unknown orgin) using Tyr 04 peptide as substrate incubated for 1 hr in presence of 25 uM ATP by FRET based Z'-LYTE assay | | | |
| AID1911600 | Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by trilux reader method | 2022 | Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
| Discovery of 1,6-Naphthyridin-2(1 |
| AID1313608 | Inhibition of recombinant human VEGFR2 using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA | 2016 | Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
| Discovery of 3-(5'-Substituted)-Benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis, and Biological Evaluation. |
| AID1601509 | Inhibition of FGFR2 (unknown origin) using poly[Glu:Tyr] (4:1) substrate and ATP and [gamma33P]-ATP incubated for 30 mins | 2019 | Journal of medicinal chemistry, 03-28, Volume: 62, Issue:6
| Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects. |
| AID1778525 | Inhibition of FGFR2 (unknown origin) | 2021 | European journal of medicinal chemistry, Aug-05, Volume: 220 | Design, synthesis and biological evaluations of a series of Pyrido[1,2-a]pyrimidinone derivatives as novel selective FGFR inhibitors. |
| AID1584378 | Inhibition of recombinant FGFR4 (unknown origin) using poly (Glu,Tyr) 4:1 as substrate after 60 mins by ELISA | 2018 | Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
| Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors. |
| AID1601511 | Inhibition of FGFR4 (unknown origin) using poly[Glu:Tyr] (4:1) substrate and ATP and [gamma33P]-ATP incubated for 30 mins | 2019 | Journal of medicinal chemistry, 03-28, Volume: 62, Issue:6
| Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects. |
| AID1717911 | Inhibition of FGFR4 in mouse BAF3 cells assessed as decrease in FGFR4 phosphorylation incubated for 40 mins | 2020 | Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
| Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4. |
| AID1904744 | Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth incubated for 5 days by SRB assay | | | |
| AID1313605 | Inhibition of recombinant human FGFR1 using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA | 2016 | Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
| Discovery of 3-(5'-Substituted)-Benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis, and Biological Evaluation. |
| AID1911525 | Antiproliferative activity against human SNU-16 cells expressing FGFR2 assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay | 2022 | Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
| Discovery of 1,6-Naphthyridin-2(1 |
| AID1911597 | Inhibition of FGFR2 (unknown origin) incubated for 30 mins by trilux reader method | 2022 | Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
| Discovery of 1,6-Naphthyridin-2(1 |
| AID1313606 | Antiproliferative activity against FGFR1-amplified human NCI-H1581 cells after 72 hrs by CCK8/MTT assay | 2016 | Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
| Discovery of 3-(5'-Substituted)-Benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis, and Biological Evaluation. |
| AID1601514 | Selectivity index, ratio of IC50 for VEGFR2 (unknown origin) to IC50 for FGFR3 (unknown origin) | 2019 | Journal of medicinal chemistry, 03-28, Volume: 62, Issue:6
| Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects. |
| AID1601510 | Inhibition of FGFR3 (unknown origin) using poly[Glu:Tyr] (4:1) substrate and ATP and [gamma33P]-ATP incubated for 30 mins | 2019 | Journal of medicinal chemistry, 03-28, Volume: 62, Issue:6
| Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects. |
| AID1717910 | Inhibition of FGFR4 in mouse BAF3 cells assessed as reduction in cell viability incubated for 2 days by cell proliferation assay | 2020 | Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
| Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4. |
| AID1584377 | Inhibition of recombinant FGFR1 (unknown origin) using poly (Glu,Tyr) 4:1 as substrate after 60 mins by ELISA | 2018 | Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
| Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors. |
| AID1345535 | Human fibroblast growth factor receptor 3 (Type V RTKs: FGF (fibroblast growth factor) receptor family) | 2011 | Molecular cancer therapeutics, Nov, Volume: 10, Issue:11
| A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. |
| AID1345506 | Human kinase insert domain receptor (Type IV RTKs: VEGF (vascular endothelial growth factor) receptor family) | 2011 | Molecular cancer therapeutics, Nov, Volume: 10, Issue:11
| A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. |
| AID1345514 | Human fibroblast growth factor receptor 1 (Type V RTKs: FGF (fibroblast growth factor) receptor family) | 2011 | Molecular cancer therapeutics, Nov, Volume: 10, Issue:11
| A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. |
| AID1345517 | Human fibroblast growth factor receptor 2 (Type V RTKs: FGF (fibroblast growth factor) receptor family) | 2011 | Molecular cancer therapeutics, Nov, Volume: 10, Issue:11
| A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. |
| AID1345568 | Human fibroblast growth factor receptor 4 (Type V RTKs: FGF (fibroblast growth factor) receptor family) | 2011 | Molecular cancer therapeutics, Nov, Volume: 10, Issue:11
| A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |